{"doi":"10.1101/2025.03.31.646290","title":"Associations between fluid biomarkers and PET imaging ([ <sup>11</sup> C]UCB-J) of synaptic pathology in Alzheimer’s disease","abstract":"ABSTRACT INTRODUCTION Positron Emission Tomography (PET) imaging with ligands for synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising methodology for measuring synaptic density in Alzheimer’s disease (AD). We investigate the relationship between SV2A PET and CSF synaptic protein changes of AD patients. METHOD Twenty-one participants with early AD and 7 cognitively normal (CN) individuals underwent [ 11 C]UCB-J PET. We used mass spectrometry to measure a panel of synaptic proteins in CSF. RESULTS In the AD group, higher levels of syntaxin-7 and PEBP-1 were associated with lower global synaptic density. In the total sample, lower global synaptic density was associated with higher levels of AP2B1, neurogranin, γ-synuclein, GDI-1, PEBP-1, syntaxin-1B, and syntaxin-7 but not with the levels of the neuronal pentraxins or 14-3-3 zeta/delta. CONCLUSION Reductions of synaptic density found in AD compared to CN participants using [ 11 C]UCB-J PET were observed to be associated with CSF biomarker levels of synaptic proteins.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2025,"id":557475,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8971,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":235253,"name":"Adam P. Mecca","orcid":"0000-0003-1982-5443","position":1,"is_corresponding":false},{"id":241104,"name":"Nicholas J. Ashton","orcid":"0000-0002-3579-8804","position":2,"is_corresponding":false},{"id":66824,"name":"Elaheh Salardini","orcid":null,"position":3,"is_corresponding":false},{"id":235254,"name":"Ryan S. O’Dell","orcid":"0000-0001-7673-6661","position":4,"is_corresponding":false},{"id":235261,"name":"Richard E. Carson","orcid":"0000-0002-9338-7966","position":5,"is_corresponding":false},{"id":273184,"name":"Andréa L. Benedet","orcid":null,"position":6,"is_corresponding":false},{"id":27600,"name":"Kaj Blennow","orcid":"0000-0002-1890-4193","position":7,"is_corresponding":false},{"id":27601,"name":"Henrik Zetterberg","orcid":"0000-0003-3930-4354","position":8,"is_corresponding":false},{"id":235262,"name":"Christopher H. van Dyck","orcid":"0000-0003-1779-097X","position":9,"is_corresponding":false},{"id":585722,"name":"Ann Brinkmalm","orcid":"0000-0002-7396-3233","position":10,"is_corresponding":false},{"id":817707,"name":"Johanna Nilsson","orcid":"0000-0002-2856-6060","position":0,"is_corresponding":true}],"reference_count":33,"raw_metadata":null,"created_at":"2026-07-19T02:55:17.435961Z","pmid":"40236111","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}